| Domain | Best current finding | Quantitative detail | Evidence type/strength |
|---|---|---|---|
| Disease identity | PUS3-related neurodevelopmental disorder is the same entity referred to in OMIM as NEDMIGS: neurodevelopmental disorder with microcephaly and gray sclera (OMIM #617051); gray sclera is not consistently present | 21 reported individuals from 15 families in the main aggregate cohort; gray/blue sclera in 7 individuals overall | Human clinical aggregate cohort; strongest disease-level summary currently available (pqac-00000002, pqac-00000017, pqac-00000018) |
| Gene and inheritance | Caused by biallelic PUS3 variants; autosomal recessive pattern supported by homozygous and compound-heterozygous cases with unaffected parents | 10/21 homozygous; 11/21 compound heterozygous | Human genetic evidence from multiple families; strong (pqac-00000001, pqac-00000012, pqac-00000015) |
| Cohort size/demographics | Largest delineation collected published and new cases internationally | Age at evaluation 8 months-44 years; median 13 years; no sex difference | Human clinical cohort; moderate-strong for phenotype frequencies, limited by retrospective aggregation (pqac-00000002, pqac-00000018) |
| Core neurodevelopmental phenotype | Disorder is dominated by intellectual disability/global developmental delay, speech impairment, motor delay, hypotonia, microcephaly, and facial dysmorphism | ID 19/19 (100% among assessed); impaired speech 11/11 (100%); motor delay 16/18 (88%); hypotonia 10/13 (77%); microcephaly/anencephaly 13/18 (72%); facial dysmorphism 17/18 (94%) | Human clinical aggregate evidence; strong for recurrent features, but denominators vary by reported assessment (pqac-00000004, pqac-00000017, pqac-00000018) |
| Epilepsy | Epilepsy is common but variable in onset, seizure type, and treatment response | 13/18 (72%); onset 1.5 months-18 years, median 22.5 months; 3/7 with available data achieved seizure freedom on treatment; EEG documented in 9, epileptiform discharges in 3 | Human clinical evidence; moderate due to incomplete ascertainment and heterogeneous follow-up (pqac-00000002, pqac-00000018) |
| Neuroimaging and ancillary findings | Brain MRI may be normal or abnormal; common reported abnormalities include atrophy/hypoplasia and white-matter changes; growth/skeletal/behavioral issues are frequent | MRI abnormal 11/15 (73%), normal 4/15; short stature 10/17 (59%); scoliosis 8/10 (80%); behavioral features in 11/19; autism features in 4/6 assessed | Human clinical aggregate evidence; moderate (pqac-00000015, pqac-00000018) |
| Severe infant presentation | One reported Chinese infant had a severe epileptic encephalopathy/malformation presentation that broadens severity spectrum | Male infant, 8 months; compound heterozygous c.55C>T (p.Arg19*) and c.620dupT (p.Thr208fs); MRI with dilated cisterna magna and bilateral frontotemporal extracerebral space; metabolic screens normal | Single-patient case report; useful for edge phenotype, lower generalizability (pqac-00000008) |
| Variant spectrum | Broad allelic heterogeneity with missense and loss-of-function alleles; several recurrent variants exist | 17 distinct PUS3 variants in 21 individuals: 8 missense, 7 protein-truncating, 1 splice, 1 initiation-codon substitution | Human aggregate genetics; strong descriptive evidence (pqac-00000001, pqac-00000015, pqac-00000016) |
| Direct functional mechanism | Pathogenic variants can reduce PUS3 function by destabilizing or aggregating the protein, causing depletion of cellular PUS3 and reduced PUS3-dependent pseudouridylation in patient fibroblasts despite near-normal in vitro catalytic behavior for Y71C | In 3 patients, p.Tyr71Cys and p.Ile299Thr were linked to strongly reduced PUS3 protein and reduced PUS3-dependent Ψ levels in fibroblasts; Y71C preserved in vitro tRNA binding/activity but impaired thermostability; I299T promoted aggregation | Patient fibroblasts + recombinant protein assays; strongest direct mechanistic evidence available (pqac-00000000, pqac-00000003, pqac-00000007, pqac-00000011, pqac-00000014) |
| Molecular function/pathophysiology | PUS3 is a TruA/Pus3-family pseudouridine synthase that modifies tRNA anticodon-loop uridines (positions 38-39); deficiency likely impairs tRNA stabilization/biogenesis and downstream translation important for brain development; mitochondrial contribution remains plausible but unproven | PUS3 modifies U38/U39 of tRNA; localized in cytoplasm and mitochondria according to disease review/case synthesis | Integrated human genetics + biochemical inference; moderate, with some steps still inferential (pqac-00000004, pqac-00000015, pqac-00000017) |
| Diagnosis | Diagnosis currently depends on molecular testing rather than a pathognomonic clinical signature | Identified by exome sequencing, whole-genome sequencing, or virtual gene panels; parental testing performed in reported families | Human real-world diagnostic implementation; strong for current practice (pqac-00000017, pqac-00000018) |
| Treatment and real-world management | No disease-specific therapy exists; care is supportive and symptom-directed, especially antiseizure therapy and rehabilitation | In the severe infant case, sodium valproate gave incomplete control with seizures about every 3 months; in the pooled cohort, seizure control was variable and 3/7 achieved seizure freedom | Human case-based management evidence only; weak for treatment efficacy (pqac-00000008, pqac-00000018) |
| Trials and translational pipeline | No relevant interventional clinical trials were identified for PUS3-related disorder | 0 relevant PUS3-specific trials found in tool search | Trial search evidence; strong for current absence of registered disease-specific trials in searched sources (tool search result summarized in conversation; no context ID available for citation, so omitted from citation field) |
| Major evidence gaps | No robust prevalence/incidence estimates, natural-history cohorts, validated biomarkers, genotype-specific management guidelines, or established disease animal models were identified; newer 2023-2024 literature is mostly broad RNA-modification review rather than disease-specific clinical advance | Epidemiology unknown; no disease-modifying therapy; no validated single-cell/spatial/multi-omics disease datasets identified in reviewed evidence | Evidence-gap synthesis from available human/mechanistic literature; moderate confidence in absence from searched sources (pqac-00000002, pqac-00000015, pqac-00000017) |


*Table: This table summarizes the strongest currently available evidence for PUS3-related neurodevelopmental disorder across identity, genetics, phenotype, mechanism, diagnosis, treatment, and gaps. It is useful as a compact knowledge-base scaffold because the literature is sparse and distributed across a few key reports.*